
The report states that the use of bio-implants enables faster treatment with negligible complications and this makes them preferable over the conventional forms of implants. As per this research study, the market for bio-implants is predicted to grow exponentially owing to the swiftly developing healthcare infrastructure in developing as well as developed regions. In addition, the rising occurrence of chronic health disorders, particularly in the geriatric population, along with the increasing disposable incomes of people, is predicted to boost the bio-implants market. On the other hand, factors such as soaring costs of treatment and reimbursement problems may inhibit the growth of the market in forthcoming years. In terms of type of implant, the market is segmented into autografts, allografts, and xenografts. On the basis of therapeutic area, the report segments the market into dental, orthopedic, ophthalmic, and others.
As per this study, on the basis of geography, the market is segmented into Europe, North America, Asia Pacific, and Rest of the World (RoW). Amongst these, North America led the market in 2012 and was trailed by Asia Pacific and Europe. However, the market for bio-implants is expected to face a downturn in the region of North America owing to the rising austerity measures and taxation by the Federal government. In addition, within European countries, the ongoing euro crisis is also predicted to impede the growth of the market. The region of Asia Pacific is anticipated to experience swift growth in the coming years owing to rising foreign investments and government funding, as mentioned in this report.
According to this study, the chief players operating in the market for bio-implants are Biomet, Inc. (U.S.), Tornier N.V. (The Netherlands), Smith & Nephew (U.K.), Stryker Corporation (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical, Inc. (U.S.), Medtronic (U.S.), Synthes (U.S.), and others.
No comments:
Post a Comment